ZOM Stock Price: Zomedica Corp extends rally following year end 2020 results

NYSEAMERICAN:ZOM gained a further 2.91% on Tuesday despite the border market retreat.
Zomedica reported its Q4 and year end 2020 earnings results on Friday after the closing bell.
Investors continue to believe that the impending Truforma release will launch Zomedica to a huge windfall.

Stocks Reporter FXStreet

NYSEAMERICAN:ZOM continued its stellar year ever since the calendar flipped to 2021, as the pet diagnostic company is still up over 500% year to date. Tuesday saw Zomedica continue its momentum from Monday as the stock gained 2.91% to close the trading session at $2.12. It has been less than a year since Zomedica was trading as a penny stock as is evident by its 52-week low price of $0.06. In the meantime, Zomedica briefly rode the wave of being a target of the Reddit sugroup r/WallStreetBets which accounted for much of the rise in the stock’s price.

Stay up to speed with hot stocks' news!

On Friday, Zomedica released its Q4 and year end 2020 financial results, and the news was somewhat optimistic for a company that has zero revenues to date. Losses were lower year-over-year from 2019, as ZOM announced losses of $16.9 million in 2020 compared to $19.8 million in 2019. This equates to roughly losses of $0.05 per share compared to $0.19 per share in 2019. Zomedic also reported it had nearly $280 million in the bank after several rounds of stock offerings to raise cash and take advantage of its current stock price.

ZOM stock forecast

Of course, the main focus for Zomedica investors continues to be the upcoming release of its Truforma pet diagnostic platform at the end of March. While a nationwide rollout does not seem to be in the cards, Zomedica is taking its time with a staggered, regional rollout, which should help keep costs lower, but at the same time, limit the rate of sales growth.

Author

Stocks Reporter

FXStreet

GBP/USD extends the drop to 1.3360

GBP/USD builds on Monday’s decline and briefly clinches five-day lows near 1.3360 on Tuesday. Cable’s extra pullback follows the better tone in the Greenback as uncertainty in the Middle East prompts investors to adopt a cautious stance. Meanwhile, an apathetic UK labour market report also collaborates with the selling pressure on the British Pound.

EUR/USD stays offered just above 1.1400

EUR/USD keeps the downtrend well in place for yet another day, challenging the 1.1400 contention zone on Tuesday. The continuation of the selling impulse in spot comes amid decent gains in the US Dollar, which continues to find support in the persistent effervescence surrounding the US-Iran crisis.

Middle East crisis intensifies, Gold up

Gold now seems to have embarked on a consolidative phase below the key $4,100 mark per troy ounce in the latter part of Tuesday’s session. Meanwhile, uncertainty surrounding the Middle East conflict and rising expectations for a hawkish Fed policy outlook are expected to limit the precious metal’s bullish momentum in the near term.

XRP rebounds on rising on-chain activity

Ripple (XRP) ticks up and trades around $1.13 at the time of writing on Tuesday. This rebound aligns with a broader recovery in the cryptocurrency market, attributed to reports that mediators between the United States (US) and Iran are seeking a 10-day cessation of strikes to find a way back to the signed Memorandum of Understanding (MoU).

The Iranian war has again risen

The Iranian war has again risen to the top of the economics factor list. There is no end in sight. Intelligence experts say the current level of offense/retaliation will not change minds in Tehran, while in Washington, Trump fears all-out war, which would mean boots on the ground.

US Dollar mid-year outlook: Exceptional currency, exceptional risks?

The US Dollar enters the second half of 2026 in a markedly different position from a year ago. The King currency has recovered, reflecting persistent US inflation, changing expectations for Fed policy, geopolitical tensions and renewed demand for defensive assets.